Evidence map›Paper›PMID 41122177›Full record

SynthesisFrontiers in immunology2025

Predicting immune checkpoint inhibitors response via fluorescence lifetime imaging microscopy: a systematic review.

Carlo Cossa, Giulio Frigato, Massimo Lupo, Gabriele Mazzeo, Alex Moro, Francesco Patrucco, Reanna Wang, Andrea Doni, Piergiuseppe Colombo

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carlo Cossa *Humanitas University, Milan, Italy.
Giulio Frigato *Humanitas University, Milan, Italy.
Massimo Lupo *Humanitas University, Milan, Italy.
Gabriele Mazzeo *Humanitas University, Milan, Italy.
Alex Moro *Humanitas University, Milan, Italy.
Francesco Patrucco *Humanitas University, Milan, Italy.
Reanna WangHumanitas University, Milan, Italy.
Andrea DoniUnit of Multiscale and Nanostructural Imaging, IRCCS Humanitas Research Hospital, Milano, Italy.
Piergiuseppe ColomboDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fluorescence Lifetime Imaging Microscopy (FLIM) is an imaging technique that allows for the visualization of the cellular microenvironment by measuring the decay time of endogenous fluorescent molecules. Its advent has allowed the acquisition of information on previously undetectable aspects of the tissue environment, which also includes some mechanisms involving immune checkpoints. Understanding the level of interaction with their ligands is of paramount importance when stratifying patients for immunotherapy, as traditional methods such as immunohistochemistry (IHC) were found to be ineffective in predicting responders. Methods: This review analyzes the current literature on FLIM as a means of predicting targets' responsiveness to ICIs by examining the most relevant databases. Following PRISMA guidelines, we identified the relevant literature. The predefined objective of this review was to evaluate the potential of FLIM as a predictive biomarker of responsiveness to immune checkpoint inhibitors (ICIs). Eligibility criteria included original studies (clinical or preclinical) reporting on the use of FLIM to assess tumor or immune microenvironment in the context of ICI therapy. Reviews, case reports, editorials, and abstracts without full text were excluded. Results: Research suggests that interaction, not expression, is positively correlated with the effectiveness of ICI treatment. FLIM, in combination with FRET, allows for the quantification of the interactions within the tumor microenvironment. Discussion: The scope of the review is to assist researchers in further exploring this technology for possible applications and for future drug interaction studies.

Indexed as

Immune Checkpoint InhibitorsNeoplasmsAnimalsHumansMicroscopy, FluorescenceTreatment OutcomeTumor MicroenvironmentImmune Checkpoint InhibitorsCTLA4FLIMICIIFRETimmunotherapyPD1PDL1

Identifiers

PMID41122177
PMCPMC12535979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.